Board Meeting24 Jul 2026, 01:52 pm
Dr. Lal PathLabs Board Approves Interim Dividend, Stock Options, and Acquisitions
AI Summary
Dr. Lal PathLabs Ltd's Board of Directors convened on July 24, 2026, approving the un-audited financial results for the quarter ended June 30, 2026. The board also declared an interim dividend of ₹5 per equity share for FY 2026-27, with a record date of July 30, 2026. Additionally, stock options were approved for eligible employees under the Restricted Stock Unit Plan 2025. The board was also informed of two key acquisitions: Dr Lal PathLabs FZCO, Dubai (a wholly-owned subsidiary) approved the acquisition of a stake in Sunshine Healthcare Limited, Ghana, and Dr. Lal Ventures Private Limited (a wholly-owned subsidiary) approved the acquisition of a stake in Neuome Technologies Private Limited.
Key Highlights
- Approved un-audited financial results for Q1 FY27.
- Declared interim dividend of ₹5 per share for FY27.
- Granted stock options under the Employee Restricted Stock Unit Plan 2025.
- Subsidiaries approved acquisitions in Ghana and India.
- Board meeting held on July 24, 2026.
Price Impact
More from LALPATHLAB